SDC, Materials and Methods: Exclusion Criteria at Screening and at Week 4.

Exclusion criteria at screening
• Received an organ transplant other than a kidney • Received an organ from an HLA-identical donor • Cold ischemia time >24 hours • Received a graft from a non-heart-beating donor other than of Maastricht category 3 • Significant liver disease, defined as having continuously elevated alanine aminotransferase and/or aspartate aminotransferase and/or total bilirubin levels ≥2x ULN of the investigational site • Received a graft from a hepatitis C- or B-positive donor • Required on-going dosing with a systemic immunosuppressive drug prior to transplantation (eg, for Lupus disease, etc.) other than minimal levels of immunosuppressive following failure of a previous transplantation without nephrectomy • Significant, uncontrolled concomitant infections and/or severe diarrhea, vomiting, active upper gastro-intestinal tract malabsorption, or active peptic ulcer • Patient or donor HIV positive • Known allergy or intolerance to tacrolimus, macrolide antibiotics, steroids, lactose, basiliximab, MMF, or to any of the product excipients • Patient had malignant tumor (except patients who did not have a recurrence of malignant tumor ≥5 years before signing the informed consent form

- Participating in another clinical study and/or had taken an investigational drug ≤12 weeks before signing the informed consent form
- Any form of substance abuse, psychiatric disorder, or condition that, in the opinion of the investigator, could complicate communication with the investigator
- Unlikely to comply with the visits scheduled in the protocol
- Patient who had no plan to receive the induction therapy at transplantation
- Expanded-criteria donor kidney (UNOS/OPTN)
- Patient with a high immunologic risk, defined as:
    1. PRA level >50% in the previous 52 weeks
    2. DSA positive before transplantation
    3. T and/or B cell cross-match positive before transplantation
    4. Previous graft loss <52 weeks prior to current transplantation due to immunologic reasons

Exclusion criteria at Week 4[*]

- Did not receive basiliximab induction therapy at the time of transplantation
- Dose adjustment after Week 4 was contraindicated due to a recent rejection episode, such that treatment finished within 7 days
- Cold ischemia time >24 hours
- Delayed graft function (patient required more than one dialysis treatment in the first week following transplantation)
- Pre-transplant DSA result was found to be positive

DSA, donor-specific antibody; HIV, human immunodeficiency virus; HLA, human leukocyte antigen; MMF, mycophenolate mofetil; OPTN, Organ Procurement and Transplantation

Network; PRA, panel reactive antibody; ULN, upper limit of normal; UNOS, United Network for Organ Sharing.

*Patients were excluded from the study between Day 0 and Week 4 if one of the five exclusion criteria were present.